Figure 6.

Antitumour activity of PMX/CPT-11 combination against pancreatic cancer xenografts. MIA PaCa2, CFPAC-1 and PACA3 xenograft tumours established subcutaneously in athymic nude mice were randomised to treatment groups (n=5 mice pergroup). The treatment groups were untreated controls (black symbol: PBS i.p.), GEM alone (white symbol: 150 mg kg⁻¹ i.p. on days 0, +3, +6, +9, +12, +15, +18, +21) or PMX/CPT-11 after GEM treatment (grey symbol: GEM 150 mg kg⁻¹ i.p. on days 0, +3, +6, +9; PMX 100 mg kg⁻¹ i.p. on every day starting from day +12 until day +21; CPT-11 50 mg kg⁻¹ i.p. on days +12 and +17) Data are expressed as the median change (fold increase) in tumour volume relative to volume on day 0, when treatment was initiated (MIA PaCa2=89.288 mm³; CFPAC-1=65.46 mm³; PACA3=261.87 mm³).